Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 15/20 | 0.74 |
| ▸ | NPC1 | O15118 | 5/20 | 0.64 |
| ▸ | RAB9A | P51151 | 5/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.57 |
| ▸ | RELA | Q04206 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | CNR2 | P34972 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17014746 | 0.85 | AR (1.00) | ARNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL18674685 | 0.84 | AR (0.73) | ARNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL18674637 | 0.84 | AR (0.83) | ARNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL17014763 | 0.83 | AR (0.77) | ARNPC1RAB9ASMN1; SMN2MAPT | |
| Bromide SCHEMBL10874774 | 0.83 | AR (0.71) | ARNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL17014752 | 0.83 | AR (1.00) | ARNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL27413114 | 0.83 | AR (0.67) | ARNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL17014745 | 0.83 | AR (0.74) | ARNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL17014783 | 0.82 | AR (0.71) | ARNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL25649388 | 0.82 | AR (0.77) | ARNPC1RAB9ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | disclosed |
| US-9993409-B2 | Composition for dyeing keratin fibres, comprising an oxidation base and a particular heteroaryl coupler | L'OREAL (FR) | 2018-06-12 | — | — | US | disclosed |
| US-20170087075-A1 | COMPOSITION FOR DYEING KERATIN FIBRES, COMPRISING AN OXIDATION BASE AND A PARTICULAR HETEROARYL COUPLER | L'OREAL (FR) | 2017-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170087075-A1 | COMPOSITION FOR DYEING KERATIN FIBRES, COMPRISING AN OXIDATION BASE AND A PARTICULAR HETEROARYL COUPLER | KRT18, F12, CBR3 | AR 562/4885NPC1 4834/4885RAB9A 3590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.